37 / 88
HIPERTENSIÓN / 2016 / VOL. 21
37
BIBLIOGRAFÍA
1.
Kurtz A. Renin release: sites, mechanisms, and control. Annu. Rev. Physiol. 2011;73:377-399.
2.
Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical Renin-Angiotensin system in kidney physiology. Compr. Physiol.
2014;4(3):1201-1228.
3.
Laragh JH. Laragh ’ s Lessons in Pathophysiology and Clinical Pearls for Treating Hypertension. Am. J. Hypertens. 2001;14:186-194.
4.
Silver RB, Reid AC, Mackins CJ, et al. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A 2004;101(37):13607-13612.
5.
Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias
in ischemia/reperfusion. J. Clin. Invest. 2006;116(4):1063-1070.
6.
Iervasi A, Zucchelli GC, Turchi S, et al. Analytical and clinical performance of an automated chemiluminescent immunoassay for direct renin measurement :
comparison with PRA and aldosterone assays Performances analytiques et cliniques d ’ une méthode automatique en chemiluminescence pour la
mesur. Immuno-analyse Biol. spécialisée 2005;20:257-262.
7.
Oshima Y. Roles of the (pro)renin receptor in the kidney. World J. Nephrol. 2014;3(4):302-307.
8.
Deinum J, Rønn B, Mathiesen E, Derkx FHM, Hop WCJ, Schalekamp MADH. Increase in serum prorenin precedes onset of microalbuminuria in
patients with insulin-dependent diabetes mellitus. Diabetologia 1999;42(8):1006-1010.
9.
Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased Plasma Inactive Renin in Diabetes Mellitus. N. Engl. J. Med.
1985;312(22):1412-1417.
10. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-b1 and matrix proteins through receptor-
mediated, angiotensin II-independent mechanisms. Kidney Int. 2006;69:105-113.
11. Morganti A. A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a
new chemiluminescent assay of immunoreactive renin. J. Hypertens. 2010;28(6):1307-12.
12. Liaison Direct Renin. DiaSorin Instructions insert. Latest version.
13. Lonati C, Bassani N, Gritti A, Biganzoli E, Morganti A. Measurement of plasma renin concentration instead of plasma renin activity decreases the
positive aldosterone-to-renin ratio tests in treated patients with essential hypertension. J. Hypertens. 2014;32(3):627-34.
14. Laragh JH. Laragh ’ s Lessons in Pathophysiology and Clinical Pearls for Treating Hypertension. 2001;14:491-503.
15. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine
Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2016;101(5):1889-1916.
16. Olson N, Dejongh B, Hough A, Parra D. Plasma Renin Activity – Guided Strategy for the Management of Hypertension. Pharmacotherapy
2012;31(5):446-55.
17. Hollenberg NK. Renin Inhibition: What Are the Clinical Perspectives? Semin. Nephrol. 2007;27(5):511-518.
18. Egan BM, Basile JN, Rehman SU, et al. Plasma Renin Test – Guided Drug Treatment Algorithm for Correcting Patients With Treated but Uncontrolled
Hypertension : A Randomized Controlled Trial. Nature 2009;22(7):792-801.
19. Shah S, Coakley C, Hough A, Parra D. Plasma Renin Activity Testing to Guide Triple Antirenin System Drug Therapy in a Patient With Difficult-to-
Treat Hypertension. Ann. Pharmacother. 2014;48(2):279-285.
20. Hiramatsu K, Yamada T, Yukimura Y, Komiya I IK. A Screening Test to Identify Aldosterone-Producing Adenoma by Measuring Plasma Renin Activity.
Arch Intern Med 1981;141:1589-1593.
21. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J. Hypertens. 2008;26(4):613-21.
22. Welch WJ. The pathophysiology of renin release in renovascular hypertension. Semin. Nephrol. 2000;20(5):394-401.
23. De Boer RA, Schroten NF, Bakker SJL, et al. Plasma renin and outcome in the community: Data from PREVEND. Eur. Heart J. 2012;33(18):2351-
2359.